Germany's Merck to Use Cenix's RNAi Service to Screen for Drugs | GenomeWeb
NEW YORK (GenomeWeb News) – Cenix BioScience today said German drug maker Merck will use its RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
 
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
 
Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.